Unravel the Science of Ongoing VOC Damage in Sickle Cell Disease

Vaso-occlusive crises (VOCs) are the clinical hallmark of sickle cell disease (SCD), and originate from ongoing, silent, vaso-occlusion, which is primarily caused by multicellular adhesion.^1-3

Learn More

Rethink
Sickle
Cell
Disease

The most common genetic blood disorder in the United States⁴

❯

test

SCD goes beyond red blood cells and, early on, progresses to a chronic vascular disease³

❯

test

Multicellular adhesion among endothelium and blood cells is a major driver of vaso-occlusion and VOCs³

❯

test

The upregulation and expression of specific adhesion mediators, including E-, L- and P-selectin, drives multicellular adhesion clusters^3,5

❯

test

SCD can impact all organs in the body, and VOCs increase the risk of organ damage, multiorgan failure, and death^3,6,7

❯

test

The impact of SCD and VOC burden is associated with decreased quality of life, including cognitive and social aspects^8-10

❯

test

SCD is associated with increased health care costs, with VOCs being the primary reason for ER visits^11,12

❯

test

Rethink
Sickle Cell Disease

The most common genetic blood disorder in the United States⁴

❯

test

SCD goes beyond red blood cells and, early on, progresses to a chronic vascular disease³

❯

test

Multicellular adhesion among endothelium and blood cells is a major driver of vaso-occlusion and VOCs³

❯

test

The upregulation and expression of specific adhesion mediators, including E-, L- and P-selectin, drives multicellular adhesion clusters^3,5

❯

test

SCD can impact all organs in the body, and VOCs increase the risk of organ damage, multiorgan failure, and death^3,6,7

❯

test

The impact of SCD and VOC burden is associated with decreased quality of life, including cognitive and social aspects^8-10

❯

test

SCD is associated with increased health care costs, with VOCs being the primary reason for ER visits^11,12

❯

test

References:

1. Puri L, Nottage KA, Hankins JS, Anghelescu DL. State of the art management of acute vaso-occlusive pain in sickle cell disease. Paediatr Drugs. 2018;20(1):29-42. 2. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647-3656. 3. Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin. 2009;33(1):1-16. 4. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77-78. 5. Zhang D, Xu C, Manwani D, Frenette PS. Sickle cell disease: challenges and progress. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809. 6. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561-1573. 7. American Society of Hematology. State of Sickle Cell Disease: 2016 Report. Washington, DC: 2016. http://www.scdcoalition.org/report.html. 8. Hasan S, Hashmi S, Alhassen M, Lawson W, Castro O. Depression in sickle cell disease. J Natl Med Assoc. 2003;95(5):533-538. 9. Swanson ME, Grosse SD, Kulkarni R. Disability among individuals with sickle cell disease. Am J Prev Med. 2011;41(6S4):S390-S397. 10. Brandow AM, Brousseau DC, Panepinto JA. Post-discharge pain, functional limitations, and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol. 2009;144(5):782-788. 11. Lentz MB, Kautz DD. Acute vaso-occlusive crisis in patients with sickle cell disease. Nursing2018. 2017;41(1):67-68. 12. Lanzkron S, Carroll CP, Haywood C. The burden of emergency department use for sickle cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85(10):797-799.

Unravel the Science of Ongoing VOC Damage in Sickle Cell Disease

Learn more about the ongoing damage in sickle cell disease and the impact of vaso-occlusive crises

For US HCPs